Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
3.910
-0.010 (-0.26%)
At close: Sep 15, 2025, 4:00 PM EDT
3.840
-0.070 (-1.79%)
After-hours: Sep 15, 2025, 7:49 PM EDT
Kyverna Therapeutics Employees
Kyverna Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 16 or 16.67% compared to the previous year.
Employees
112
Change (1Y)
16
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,416,938
Market Cap
169.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KYTX News
- 14 hours ago - Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - GlobeNewsWire
- 18 days ago - Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event - GlobeNewsWire
- 21 days ago - Kyverna Therapeutics to Present at Upcoming Investor Conferences in September - GlobeNewsWire
- 26 days ago - Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 - Benzinga
- 4 weeks ago - Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise - PRNewsWire
- 3 months ago - Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 3 months ago - With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga